Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.

The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.

American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.

In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization

Source: PubMed Petri M, Konig MF, Li J, Goldman DW. Higher Hydroxychloroquine Blood Levels Are Associated with Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis …

No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.

Bengal has released this document to state their COVID-19 policies, which include the use of HCQ. Well done Bengal.

Adjunct Prof John SkerrittDeputy SecretaryHealth Products Regulation GroupJohn.Skerritt@health.gov.auGPO Box 9848, Canberra, ACT Dear Professor Skerritt,We are writing to express our concerns regarding the role of …

Source: Research Square. Augusto Di Castelnuovo, Mediterranea Cardiocentro, NapoliSimona Costanzo, Department of Epidemiology and Prevention, IRCCS Neuromed, PozzilliAntonio Cassone, Polo della genomica, genetica e biologia, …

Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria.

Source: Science Direct Eman Sheshah, Shaun Sabico, Rashed M. Albakr, Anmar A. Sultan, Khalaf S. Alghamdi, Khaled Al Madani, Hadil A. Alotair, Nasser M. Al-Daghri,Prevalence …

Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.

Source: Science Direct Dr. Deba PrasadDhibarMD(Assistant Professor)aDr. NavneetAroraMD(Senior Resident)aDr. ArpitKakkarDNB(Senior Resident)aDr. NeerajSinglaMD(Assistant Professor)bDr. RitinMohindraMD(Assistant Professor)bDr. VikasSuriMD(Additional Professor)bDr. AshishBhallaMD(Professor)bDr. NavneetSharmaMD(Professor)bDr. Mini PSinghMD(Professor)cDr. AjayPrakashPhd(Assistant Professor)dDr. LakshmiPVMMD(Professor)eDr. BikashMedhiMD(Professor)d …

Source: BioSpace SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel …

We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.

This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality

Our results can assure that hydroxychloroquine used for COVID-19 patients is safe, highly tolerable, and with minimum side effects.

Hydroxychloroquine had a modest effect on hospital length stay and days in ICU compared with Standard Care.

Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There is disagreement about whether hydroxychloroquine (HCQ) is effective as prophylaxis …

In our study, we found hydroxychloroquine wasn’t associated with significant arrhythmia clearly relating to hydroxychloroquine so it seemed the drug was very, very safe

Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.

These results are evidences to support the early use of HCQ in post exposure prophylaxis.

Source: The Lancet Summary Background Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. …

Source: MedRxiv  View ORCID ProfileSARAH M LOFGREN,  View ORCID ProfileMelanie R Nicol, Ananta S Bangdiwala,  View ORCID ProfileKatelyn A Pastick,  View ORCID ProfileElizabeth C Okafor,  View ORCID ProfileCaleb P Skipper,  View ORCID ProfileMatthew F Pullen,  View ORCID ProfileNicole W Engen,  View …

Source: Dr Simone Gold Frontline Doctors’ Dr Simone Gold tweets: Nevada is now the 7th state to quietly reverse their decision to block HCQ prescriptions for …

Source: Pan African Medical Journal Mary Eyram Ashinyo1,&, Vida Duti2, Stephen Dajaan Dubik3, Kingsley Ebenezer Amegah4, Selorm Kutsoati5, Ebenezer Oduro-Mensah6, Peter Puplampu7, Martha Gyansa-Lutterodt8, Delese …

Source: MedRxiv Tarek Sulaiman,  View ORCID ProfileAbdulrhman Mohana, Laila Alawdah, Nagla Mahmoud, Mustafa Hassanein, Tariq Wani, Amel Alfaifi, Eissa Alenazi, Nashwa Radwan, Nasser AlKhalifah, Ehab Elkady, Manwer AlAnazi, Mohammed Alqahtani, Khalid Abdalla, Yousif Yousif, Fouad AboGazalah, Fuad Awwad, Khaled AlabdulKareem, Fahad AlGhofaili, Ahmed AlJedai, Hani Jokhdar, Fahad Alrabiah doi: https://doi.org/10.1101/2020.09.09.20184143 Abstract ABSTRACT BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding …

‘’Treatment with an oral combination of hydroxychloroquine, azithromycin and zinc may REPRESENT THE BEST CURRENT THERAPEUTIC OPTION in relation to its antiviral and immunomodulatory effects’’.